BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating

​The steadfast said successful a probe enactment that the institution has yet to beryllium that its AI‑driven operating strategy tin reliably make differentiated cause candidates and meaningful diligent outcomes. BofA noted that Recursion tin bash this done repeated wins successful objective trials. The steadfast highlighted that FAP information readout for REC‑4881 is simply a coagulated start; however, the objective information from the programme is expected to materialize successful 2027.

​BofA noted that the company’s currency pain subject and concern stay affirmative components, but upcoming pipeline readouts are considered the main catalysts for gathering much assurance successful the market.

​Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) operates arsenic a clinical-stage biotechnology institution that decodes biology and chemistry by integrating technological innovations crossed biology, chemistry, automation, information science, and engineering to industrialize cause find successful the US.

While we admit the imaginable of RXRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Follow Insider Monkey connected Google News.